Jennifer Buell - Jan 9, 2023 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role: Chief Executive Officer
Signature: By: /s/ Christine Klaskin, Attorney-in-Fact for Jennifer S. Buell
Stock symbol: INKT
Transactions as of: Jan 9, 2023
Transactions value $: $399,017
Form type: 4
Date filed: 1/11/2023, 03:58 PM
Previous filing: Jan 25, 2022
Next filing: Sep 29, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INKT	Common Stock	Award	$399K	+172K	+82.4%	$2.32	381K	Jan 9, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INKT	Stock Option	Award	$0	+500K		$0.00	500K	Jan 9, 2023	Common Stock	500K	$2.32	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.
F2	$2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date.
F3	Option was granted on January 9, 2023 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.